Menopause & HRT
Red Flags — act before continuing history
| Red flag | Why dangerous | Action |
|---|---|---|
| Postmenopausal bleeding (PMB) — any bleeding >12 months after last period | Endometrial carcinoma must be excluded. Unexplained PMB not attributable to HRT: aged 55 or over → suspected cancer pathway referral; under 55 → consider one (NICE NG12, April 2026); risk increases with age and unopposed oestrogen. Assess before starting HRT. | Suspected cancer pathway referral (≥55; consider <55) |
| Unexpected vaginal bleeding on continuous combined HRT (>6 months of use) | Breakthrough bleeding after initial 3–6 months on continuous combined HRT should be investigated to exclude endometrial pathology. Early bleeding is common and expected; late bleeding is not. | Urgent TVUSS (within 6 weeks) |
| New unilateral breast lump on HRT | Combined HRT increases breast cancer risk (NICE NG23 discussion aid, 2024: about 20 extra cases per 1,000 over 20 years with 5 years of use from about age 50; 33 with 10 years). Any new breast lump requires urgent breast clinic suspected cancer pathway referral regardless of HRT status. | Breast suspected cancer pathway referral |
| DVT / PE symptoms | Oral HRT increases VTE risk ~1.8-fold. DVT or PE on oral HRT = stop oral HRT; transdermal route may be continued after haematology review. | A&E / DVT clinic |
| Symptoms of POI in woman under 40 (<45 with amenorrhoea) | Premature ovarian insufficiency (POI) is missed in 50% on first presentation. Untreated POI leads to premature cardiovascular disease, osteoporosis and cognitive decline. | Same day / urgent |
| Severe hypertension (>160/100) on oral HRT | Oral oestrogen can raise blood pressure via hepatic angiotensinogen. Switch to transdermal route which has no hepatic first-pass effect and does not increase BP. | BP management + switch route |
Safeguarding Considerations — Consider in Every Consultation
👴 Domestic abuse during menopause
- Mood change, irritability and low libido can increase relationship conflict and abuse risk
- Symptoms may mask IPV — ask directly: "Do you feel safe at home?"
- Alcohol use may increase in peri-menopausal women with poor sleep and mood symptoms
- Refer to MARAC if high risk; document DASH assessment
🧠 Mental health and capacity
- Severe perimenopausal depression may impair capacity for treatment decisions
- Women who present with cognitive symptoms — exclude depression before dementia
- Psychiatric medication interactions with HRT must be reviewed
- Women on antipsychotics may have drug-induced amenorrhoea — distinguish from menopause
👤 Older women and carer abuse
- Post-menopausal women presenting late may have delayed help-seeking due to carer responsibilities
- Financial exploitation by family members may prevent access to private HRT formulations
- Loneliness and isolation amplify somatic symptom burden
- Ensure patient is seen alone for part of consultation
🕊 POI and reproductive loss
- POI causes permanent infertility — significant psychological impact
- Refer to specialist fertility counselling before discussing HRT in POI
- Young women with POI have elevated risk of depression and anxiety
- Psychological support alongside HRT is part of good POI care
👶 Occupational impact and identity
Cognitive symptoms (brain fog, memory loss) and vasomotor symptoms (public hot flushes) directly threaten professional confidence. Up to 1 in 4 menopausal women report significant occupational impairment. Some women contemplate early retirement due to untreated symptoms.
"You mentioned work has been affected — can you tell me a bit more about what that looks like day to day? Is it the concentration, the hot flushes, or the sleep that's most disruptive?"Workplace impact score influences treatment urgency; occupational trigger may motivate treatment initiation and adherence.
💍 Relationship and intimacy
Genitourinary syndrome of menopause (GSM) causes dyspareunia and reduced libido which directly impacts intimate relationships. Partners may misinterpret symptoms as rejection. Relationship distress secondary to menopause is common and rarely volunteered.
"Has this been affecting your relationship or your sex life at all? That's something I ask everyone because it's very common and very treatable."Vaginal oestrogen addresses GSM specifically; exploring this avoids under-treatment of a significant QoL domain.
⚖️ Cultural framing of menopause
In many Western cultures, menopause is medicalised and associated with loss of femininity and ageing. In some East Asian cultures, it is viewed as liberation. A patient's cultural framing shapes her symptom severity, help-seeking behaviour and treatment preferences.
"How do you feel about this change in your body? Is it something you've been dreading, or does it feel like a natural transition for you?"Negative cultural framing amplifies symptom burden; positive reframing alongside treatment is a therapeutic intervention in itself.
💉 Alcohol, sleep and mood
Night sweats disrupt sleep architecture, leading to secondary depression, irritability and daytime fatigue. Many women increase alcohol intake to manage sleep. Alcohol worsens night sweats, creating a vicious cycle.
"A lot of women find they use alcohol or other things to help them sleep when the night sweats are bad — has that been an issue for you?"Alcohol cessation + HRT combined reduces vasomotor symptoms more than HRT alone; brief intervention for alcohol if identified.
💥 Grief and transition
For women who have not completed their family, menopause represents permanent infertility. For women whose identity is closely tied to fertility or youth, it may trigger grief or existential distress disproportionate to physical symptom burden.
"How are you feeling emotionally about this chapter in your life? Is there anything about this transition that feels particularly difficult to come to terms with?"NICE NG23 recommends CBT (in person or digital; digital options include the Wellbeing of Women app) for psychological symptoms of menopause as a primary or adjunct treatment.
📚 Health literacy and media influence
The media landscape around menopause has shifted dramatically since 2018 — from undertreatment of debilitating symptoms to occasional overclaiming of HRT benefits. Some patients have unrealistic expectations; others remain unjustifiably terrified. Health literacy shapes both.
"There's a lot of conflicting information about HRT in the press — has any of that affected how you feel about it, positively or negatively?"Recalibrate media-driven beliefs with NICE NG23 individualised risk framing; written BMS/RCOG patient information offers reliable counters to misinformation.
- Starting with LMP before patient's agenda — loses GS marks
- Not asking about breast cancer history before prescribing HRT
- Not asking about DVT/PE history before prescribing oral HRT
- Missing GSM/sexual symptoms — undermanagement of treatable symptom
- Ignoring ICE — especially WHI-related concerns about breast cancer
- Not discussing PMB as a suspected cancer pathway referral if mentioned
999 or Same-Day Hospital
Urgent assessment- DVT or PE on HRTStop oral HRT; 999 or urgent anticoagulation pathway; transdermal may be restarted after specialist review
- Stroke / TIA on oral HRT999 immediately; stop HRT; hypercoagulable screen; TIA clinic same day
- Acute severe chest painExclude MI / PE; oestrogen-related arterial thrombosis is rare but real
- Adrenal or pituitary crisis mimicking menopauseSevere hypotension, confusion, severe nausea in young woman with amenorrhoea — exclude Addison's or hypopituitarism
Same-Day / Suspected Cancer Pathway Referral
Urgent (days)- Postmenopausal bleeding (any)Not attributable to HRT: suspected cancer pathway referral if 55 or over, consider if under 55 (NICE NG12); USS endometrium; do not start HRT until investigated
- Unexpected bleeding >6m on continuous combined HRTUrgent TVUSS (within 6 weeks) per BMS 2024; endometrial assessment if above threshold or not fully seen
- New breast lump on HRTUrgent breast clinic suspected cancer pathway referral; do not delay referral for HRT review
- POI in woman <40 (amenorrhoea >4 months)Two raised FSH results 4–6 weeks apart; investigate primary cause; start HRT promptly
- Severe uncontrolled menopausal symptoms affecting safetySuicidal ideation secondary to severe perimenopausal depression — same-day MH crisis referral
GP-managed
Planned appointment- Moderate vasomotor symptoms — new HRT requestFull history, UKMEC, individualised risk discussion, HRT start
- HRT annual reviewSymptom control, side effects, bleeding pattern, CVD/breast risk update
- Switching HRT preparationsSide effects, route preference, transition planning
- Non-hormonal symptom managementCBT, venlafaxine, lifestyle if HRT declined or contraindicated
- Long-term bone and CVD risk counsellingDEXA if indicated; calcium/vitamin D; statins; lifestyle optimisation
- Starting HRT without asking about PMB
- Not flagging PMB as a suspected cancer pathway referral — patient safety failure
- Not screening for new breast lump before HRT start
- No BP check before oral HRT start — unsafe prescribing practice
- Not arranging pelvic examination / USS for PMB — patient safety failure
- Routinely ordering FSH in woman ≥45 with typical symptoms — NICE NG23 advises against this
- Missing TSH before attributing all symptoms to menopause — misdiagnosis
- Not arranging pelvic USS for PMB
"What's happening is that your ovaries are producing less oestrogen — that's the hormone that used to regulate your cycle and protect you from things like hot flushes and bone thinning. As oestrogen levels drop, your brain keeps sending signals asking for more, and that back-and-forth is what causes the flushes and night sweats. The good news is that we have very effective treatments — and the latest evidence shows that for most women, the benefits of HRT far outweigh the risks when it's started at the right time."
"I read that HRT causes breast cancer — isn't it really dangerous?"
"I completely understand that concern — there was a lot of alarming coverage about a study in 2002. But that study looked at a specific type of HRT taken by older women for a long time, and the results have since been reinterpreted. For most women in your age group, the current evidence shows the risk of breast cancer from HRT is smaller than the risk from drinking a couple of glasses of wine a day — and the benefits, for your symptoms and your bones, are real."
"I thought I just had to put up with it — isn't it just natural?"
"It's natural in the sense that it happens to every woman, but that doesn't mean you have to suffer through it. These symptoms are caused by a hormone change that we can help with — the menopause isn't something to endure, it's something we can manage together."
Menopause (≥45, 12 months amenorrhoea)
Clinical diagnosis; no FSH required. Vasomotor, mood, sleep, GSM symptoms. Confirm no red flags. Start HRT discussion.
Perimenopause (irregular cycles, symptoms)
Variable oestrogen levels — diagnosis clinical. Sequential HRT appropriate; contraception still needed.
GSM (genitourinary syndrome)
Vaginal dryness, dyspareunia, urinary urgency — treat with topical vaginal oestrogen; may not need systemic HRT
Premature ovarian insufficiency (POI, <40)
Two raised FSH results 4–6 weeks apart; refer to POI specialist; fertility implications; HRT until 51
Early menopause (40–44)
Consider FSH (symptoms + cycle change); DEXA; higher long-term bone and CV risk than natural menopause; BMS: offer HRT at least until 51
Hypothyroidism / Hyperthyroidism
TSH confirms; treat thyroid condition first or alongside. Hypothyroidism mimics menopause exactly.
Endometrial carcinoma (PMB)
Unexplained PMB = suspected cancer pathway referral if 55 or over, consider if under 55 (NICE NG12); do not start HRT; pelvic USS; endometrial biopsy if thickness ≥4mm
Ovarian cancer
CA-125 + USS if persistent bloating, pelvic pain, altered bowel habit in menopausal woman; urgent gynaecology
- Dismissing breast cancer concern without addressing it with evidence
- Not explaining WHI context when patient raises breast cancer fear
- Ordering FSH in woman ≥45 with typical symptoms — NICE NG23 advises against this
- Delaying PMB referral — suspected cancer pathway referral is mandatory
- Delaying HRT in POI while waiting for specialist
- Missing ovarian cancer in menopausal woman with new abdominal symptoms
Validate — name their expectation
Whether the patient wants HRT urgently or is afraid of it, name where she stands before offering your clinical view.
"It sounds like these symptoms have been really significantly affecting your life — you've had months of disrupted sleep and it's affecting your work. That's exactly the kind of situation where HRT can make a real difference."Explain — share your clinical reasoning
Address the breast cancer concern with current evidence (NICE NG23). Share the risk as an absolute number, not a relative risk.
"You mentioned you're worried about the breast cancer risk — starting at about 50 and using combined HRT for 5 years gives roughly 20 extra cases per 1,000 women over 20 years. To put that in context, it's of a similar size to the extra risk from regular drinking."Negotiate — offer something today
Always leave with a plan, even if HRT decision is deferred. Lifestyle and non-hormonal options can begin today.
"Whatever you decide about HRT, I'd like to start you on some things today that will definitely help — and we can revisit the HRT decision once you've had time to think about what we've discussed."Raises endorphins and serotonin; reduces thermoregulatory dysfunction; preserves bone density and muscle mass; reduces cardiovascular risk post-menopause.
Brisk walking 30 mins 5 days/week; swimming; cycling. Weight-bearing exercise additionally protects bone density more than non-impact exercise.
Reframes catastrophic thinking about flushes; reduces arousal response to vasomotor events; directly addresses perimenopausal anxiety and mood change.
NICE NG23-recommended: menopause CBT with trained therapist or Mindfulness app (Wellbeing of Women app). Available on NHS in some areas.
Alcohol is a vasodilator and triggers hot flushes. It disrupts sleep architecture and worsens night sweats. It independently increases breast cancer risk.
Advise alcohol-free evenings, particularly 3 hours before bedtime. Even modest reduction (2 nights/week off) reduces flush frequency measurably.
Phytoestrogens (soy, red clover) weakly bind oestrogen receptors. Evidence for symptom reduction is inconsistent and modest. Mediterranean diet reduces cardiovascular risk post-menopause.
Soy foods (tofu, edamame) 2–3 servings/day. Mediterranean diet — oily fish, vegetables, whole grains. Calcium-rich foods 700mg/day.
Night sweats fragment sleep by waking the patient in sympathetically aroused state. Poor sleep amplifies mood change, cognitive symptoms and cardiovascular risk.
Cool cotton night clothes and bedding; fan or open window; consistent sleep schedule; avoid caffeine after 2pm; layer bedding for easy adjustment.
Oestrogen deficiency causes rapid bone resorption; calcium and vitamin D are essential co-factors for mineralisation. Deficiency accelerates menopause-related bone loss.
Dairy products, leafy greens, fortified foods. Vitamin D supplement in UK autumn/winter; test 25-OH vitamin D if suspected deficiency; supplement at 800–2000 IU if low.
Uterus intact: must add progestogen to protect endometrium.
- Combined HRT (oestrogen + progestogen): sequential if <12 months amenorrhoea; continuous combined if ≥12 months
- Mirena IUS can provide the progestogen component alongside systemic oestrogen (patch/gel)
- Unopposed oestrogen = endometrial hyperplasia risk — prescribing error with intact uterus
Transdermal (patch/gel) preferred in:
- VTE risk factors (obesity BMI >30, immobility; prior DVT/PE or thrombophilia after specialist advice)
- Hypertension (oral HRT can raise BP; transdermal does not)
- Migraine with aura (avoids oestrogen fluctuation of oral route)
- Liver disease (avoids hepatic first-pass)
Sequential combined: for perimenopause or <12 months amenorrhoea.
- Daily oestrogen + progestogen 12–14 days a month; produces regular withdrawal bleed
- Unscheduled bleeding in the first 6 months (or 3 months after a change) is common (NICE NG23)
- Late cycle irregular bleeding (days 1–9) after 6 months: investigate endometrium
Continuous combined: for ≥12 months amenorrhoea.
- Daily oestrogen + daily progestogen; aim: no withdrawal bleed
- Irregular bleeding in first 3–6 months is common; review if persists >6 months
- Venlafaxine 37.5–75mg OD (off-label) — SNRI; reduces flush frequency ~50%; not routinely first-line for vasomotor symptoms alone (NICE NG23) — fezolinetant is an option when HRT is unsuitable; avoid with tamoxifen (paroxetine) — venlafaxine is safe
- Clonidine 50–75mcg BD — alpha-2 agonist; modest effect on flushes; useful if venlafaxine not tolerated; hypotensive side effects
- Gabapentin 100–300mg nocte — reduces nocturnal flushes; useful for sleep disruption; off-label; caution in renal impairment
- CBT — NICE NG23 first-line for psychological symptoms; reduces anxiety, low mood, cognitive symptoms
- Vaginal oestrogen (Vagifem pessaries / Ovestin cream / Estring ring) — minimal systemic absorption; suitable for most women; after breast cancer, non-hormonal products first, then by shared decision (breast specialist first if on an aromatase inhibitor); no endometrial protection needed
- DHEA (prasterone, Intrarosa) — vaginal insert; converted locally to oestrogen and testosterone; useful when systemic HRT not tolerated; licensed in UK
- Ospemifene — oral SERM for GSM; useful when vaginal application difficult; avoid in breast cancer history; licensed in UK
- Vaginal moisturisers (Replens) and lubricants: non-hormonal first-line for mild GSM
- Uterus intact (needs progestogen)
- DVT / PE history (use transdermal)
- Migraine with aura (transdermal)
- BMI >30 (transdermal preferred)
- Hypertension (transdermal preferred)
- Post-hysterectomy (oestrogen-only)
- <12 months amenorrhoea (sequential)
- ≥12 months amenorrhoea (continuous combined)
- GSM only (vaginal oestrogen)
"This is the oestrogen-only version — because you've had your womb removed, you don't need the second hormone. Take it at the same time each day."
SCA pearl: Never prescribe unopposed oestrogen if the uterus is intact — this is one of the most consequential prescribing errors in HRT and must be checked explicitly.
"Apply the patch to clean, dry, hairless skin on the buttock or lower tummy — rotate the site each time. The gel is rubbed in to the inner arm or thigh; let it dry before getting dressed."
SCA pearl: Transdermal HRT at standard doses carries little or no excess VTE risk — this is the key clinical difference from oral HRT. If a patient has risk factors for VTE, transdermal is the correct route. Stating this distinction in the SCA consultation scores a Tasks mark.
"You'll have a regular monthly bleed with this type — that's expected and reassuring. If you get any bleeding at other times, especially in the first half of your cycle, please let us know."
SCA pearl: Sequential = perimenopause. Continuous combined = post-menopause (>12 months amenorrhoea). Mixing them up = wrong preparation for patient's stage — a scored Tasks failure.
"This type aims for no monthly bleed. There may be some irregular spotting for the first few months — that's normal. If you get heavier or more regular bleeding after the first 6 months, please let us know."
SCA pearl: The most common reason for investigation during HRT review is unexpected late-cycle bleeding. Know when it's expected (first 6 months, continuous combined) vs when it needs investigation (after 6 months, or new onset in established user).
"This second hormone protects the lining of your womb. Take it at night as it can make you a little sleepy. If you've had your womb removed you don't need it at all."
SCA pearl: With transdermal oestrogen (gel/patch/spray) you must add a progestogen if the uterus is intact — Utrogestan 100mg daily (continuous) or 200mg for 12–14 days/month (sequential), or a Mirena IUS. Naming the regimen scores a Tasks mark.
"This is a single daily tablet that acts like a combined HRT — it shouldn't give you a monthly bleed. It's only suitable once your periods have stopped for a year."
SCA pearl: Tibolone is for established post-menopausal women only — offering it perimenopausally (irregular bleeding) is a scored Tasks error. Its mild androgenic effect makes it a reasonable choice where low libido is the dominant complaint.
"This is a very low dose of oestrogen applied directly to the vaginal area — it stays local and doesn't significantly raise the oestrogen in your blood. You can use it long-term and there's no need to stop it after 5 years like systemic HRT."
SCA pearl: GSM is massively under-treated. Always ask about vaginal symptoms specifically — patients rarely volunteer them. Vaginal oestrogen suits most women; after breast cancer, offer it by shared decision if non-hormonal options fail. Mentioning this scores RO and Tasks marks.
"This isn't a hormone, but it works on the brain signals that cause hot flushes — around half of women find their flushes reduce by about 50% on this. It can take 2–4 weeks to take effect."
SCA pearl: Always check: is the patient on tamoxifen? If yes, venlafaxine is safe; paroxetine is contraindicated. This is a very common SCA catch — a scored Tasks item for drug interaction awareness.
Occupational impact
Brain fog, concentration difficulties and hot flushes affect 1 in 4 menopausal women at work. Symptom burden reduces performance, increases absenteeism and may prompt early retirement.
HRT consistently improves cognitive symptoms and concentration within 3 months. Advise workplace menopause support policies (available from RCOG patient information).
Reasonable adjustments under Equality Act 2010 may include flexible hours, cooler workspace, reduced uniform requirements during peak symptoms.
"You mentioned work has been affected — after treatment most women find their concentration significantly improves within 3 months."Libido & sexual function
GSM causes dyspareunia and avoidance of sex — exacerbated by relationship tension if partner is not informed. Testosterone deficiency also contributes to low libido post-menopause.
Vaginal oestrogen addresses GSM effectively. Testosterone supplementation (off-label in UK for hypoactive sexual desire disorder) may be considered after menopause specialist input.
ISSVD and BMS guidelines recommend proactive sexual health discussion in every menopause consultation.
"Has this been affecting your sex life at all? That's very common and very treatable — I'd like to help with that specifically."Mood & mental health
Perimenopausal depression is a distinct entity — often responds to HRT alone or in combination with antidepressants. NICE NG23 (2024) recommends considering menopause-specific CBT for vasomotor symptoms and for depressive symptoms associated with menopause.
Suicidal ideation in peri-menopause is an under-recognised risk; women in mid-life have a rising suicide rate that is underappreciated by clinicians.
Do not dismiss mood symptoms as "just hormonal" — screen using PHQ-9 and refer if appropriate.
"How has your mood been? I want to make sure we're not missing any depression alongside the menopausal symptoms."Driving & safety
Cognitive symptoms and severe sleep deprivation may affect driving safety. Night shift workers with severe night sweats and sleep disruption should be counselled on driving risk.
DVLA: there is no specific menopause notification requirement, but severe cognitive impairment may require disclosure. Encourage sleep treatment (HRT, sleep hygiene) before advising on driving limitation.
Gabapentin and clonidine can cause sedation — counsel explicitly on driving when prescribing these.
"While your sleep is this disrupted, I'd encourage you to be mindful of how you feel before driving long distances."Long-term health implications
Untreated early menopause or POI significantly increases risk of cardiovascular disease, osteoporosis and possibly dementia. These are not trivial long-term consequences of oestrogen deficiency.
NICE NG23 states that HRT started before age 60 does not increase cardiovascular disease risk; it does not appear to increase dementia risk, but it should not be offered to prevent dementia (the evidence does not support a protective effect).
Lifestyle modifications (exercise, diet, calcium, vitamin D, no smoking) amplify the protective effects of HRT on bone and cardiovascular system.
"Starting treatment now, while you're in the right window of opportunity, will help your symptoms and protect your bones — and, started at your age, it is not shown to increase heart risk."Relationships & support
Partners and family members may not understand the physiological basis of mood change, irritability and low libido. Relationship strain from unexplained symptoms is common and rarely volunteered.
Signpost to menopause support organisations: Menopause Support UK, British Menopause Society patient information, Menopause Matters website.
Encourage patient to involve partner in HRT discussion where appropriate; couples who understand the biology together report better treatment adherence and relationship outcomes.
"There's a lot of really good information for partners and family members too — it can really help if the people around you understand what's happening."3 months (initial HRT review)
Assess symptom response (vasomotor, mood, sleep, GSM); check BP (oral HRT); review side effects (breast tenderness, irregular bleeding, nausea); dose titration if needed; discuss any concerns about breast cancer risk.
6–12 months (consolidation)
Switch from sequential to continuous combined if now >12 months amenorrhoea (if sequential was started over 45, consider continuous combined after 5 years or by 54, whichever first, BMS 2024); review progestogen type if intolerance evident; bleeding diary review; cervical smear if due; discuss duration of HRT (no arbitrary time limit).
Annual review (ongoing)
Symptom control; bleeding pattern; BP; BMI; breast screening (mammography up-to-date); cardiovascular risk factors; bone health if indicated; ongoing discussion of continuation vs stopping; update on safety evidence.
5-year review (HRT duration discussion)
NICE NG23: no mandatory stopping point for HRT — discuss continuation vs stopping based on ongoing symptoms and updated risk profile. For some women (POI, early menopause) HRT is appropriate until at least age 51. Breast cancer risk increases with duration but must be weighed against symptom and bone benefits.
Stopping HRT (when decided)
Gradual dose reduction preferred over abrupt cessation to reduce symptom rebound. Vaginal oestrogen may continue indefinitely regardless of systemic HRT decision. DEXA if not recently done; optimise bone health; CVD lifestyle; continue calcium/vitamin D.
Memory rule
For oral HRT: BP at 3 months then annually. For all HRT: bleeding is common in the first 6 months and within 3 months of a dose or preparation change; unscheduled bleeding beyond these windows, or heavy or persistent bleeding, needs prompt assessment (NICE NG23, April 2026; BMS). Annual breast screening reminder. No routine blood oestrogen levels needed. DEXA if POI, early menopause, or bone risk factors.
⚠ Three scenario-specific phrases — use these verbatim
Why safety-netting matters beyond clinical care
- Prescribing unopposed oestrogen with intact uterus — patient safety failure
- No PMB safety-net — mandatory
- Not discussing breast cancer risk numerically — loses Tasks mark
- Continuous combined in perimenopause — wrong preparation
- No follow-up arranged (3 months mandatory for HRT start)
- Dismissing breast cancer concern without evidence-based response
- Correct HRT type for stage (sequential/continuous combined/oestrogen-only)
- Correct route for risk profile (transdermal if VTE/HTN/obesity)
- Uterus status documented and progestogen added if intact
- Breast cancer risk communicated as absolute number
- PMB safety-netting stated explicitly
- WHI breast cancer fear addressed with empathy and updated evidence
- Patient's own goals (work, sleep, relationship) referenced in plan
- Shared decision making — patient chose HRT not clinician
- Non-hormonal options mentioned even if patient choosing HRT
- Long-term health benefit framed in terms patient values
- Closing question asked: "Is there anything else?"
Who you are
Sarah, 52 years old, secondary school deputy head teacher. Your last period was 15 months ago. Hot flushes 8–10 times/day, including 3–4 times at night. Significant sleep disruption. Your concentration and memory have deteriorated and your performance reviews have been affected. BMI 28. Mild hypertension (136/82) on amlodipine 5mg. Non-smoker.
Hidden agenda
Your mother had breast cancer at 62 and died from it. You are convinced HRT will give you breast cancer. You have read extensively online and mostly found negative information. You have also been having pain during sex for the past 6 months but are too embarrassed to mention it unless specifically asked. You are also worried your concentration problems could be early dementia.
Symptoms if asked directly
- No postmenopausal bleeding — periods stopped 15 months ago completely
- No new breast lumps; mammogram 2 years ago was clear
- Vaginal dryness and pain during sex (dyspareunia) — will only disclose if specifically asked
- Low mood and anxiety; PHQ-9 score would be around 10 (moderate)
- No DVT/PE history; no migraine; no liver disease
- No family history of VTE
Lifestyle + bonus details
- Drinks 8–10 units/week (stress-related); has increased since menopause started
- Walks 20 minutes/day but not formally exercising
- Has not been to breast screening for 2 years (avoidance due to cancer fear)
- Mother's breast cancer was ER+ — this is a specific concern if asked
Resolution: Accept the plan if the doctor: (1) Addresses the breast cancer fear with empathy and current evidence from NICE NG23 (absolute number, not relative risk); (2) Asks about and addresses the dyspareunia (vaginal oestrogen); (3) Recommends transdermal HRT rather than oral (due to hypertension); (4) Checks for PMB; (5) Arranges breast screening; (6) Offers a follow-up appointment at 3 months.
- DVT / PE on HRT (leg pain, breathlessness)
- Stroke / TIA on oral HRT
- Suicidal ideation secondary to severe perimenopausal depression
- Unexplained PMB → suspected cancer pathway referral if ≥55, consider if <55 (NICE NG12)
- New breast lump on HRT → breast clinic suspected cancer pathway referral
- Unexpected bleeding >6m on continuous combined → urgent TVUSS (within 6 weeks)
- POI in woman <40 → FSH x2 + specialist
- New HRT request (no red flags)
- Annual HRT review
- HRT preparation change
- Non-hormonal options
Always: Add progestogen if uterus intact • Consider transdermal if VTE risk / HTN / obesity • Assess PMB before HRT (NG12: refer ≥55, consider <55) • Start POI HRT promptly
Transdermal: VTE risk, hypertension, obesity (BMI>30), migraine with aura, liver disease, smoker
Vaginal: GSM only or as adjunct to systemic HRT
| HRT type | What to check | Timing | Action if abnormal |
|---|---|---|---|
| Oral HRT | Blood pressure | Before start; 3m; annually | BP >160/100 = switch to transdermal |
| Sequential combined | Bleeding diary | First 3m; ongoing | Late cycle days 1–9 bleeding after 6m = pelvic USS + endometrial biopsy |
| Continuous combined | Bleeding pattern | First 6m; ongoing | Breakthrough starting >6m = urgent TVUSS (within 6 weeks); unexplained PMB = NG12 pathway (refer ≥55, consider <55) |
| All HRT | BMI; mammogram | Annually | BMI >30 = switch oral to transdermal; mammogram overdue = refer screening |
| POI / early menopause | DEXA bone density | At diagnosis; every 2–5 yrs | T-score < −2.5 = osteoporosis; consider bisphosphonate; calcium/vit D |
→ Open with "what's been most affecting you?" — always
→ Always add progestogen or use Mirena IUS if uterus present
→ Ask PMB before any HRT; assess and refer per NG12 (≥55 refer, <55 consider); do not start HRT
→ Consider transdermal with risk factors — little or no excess VTE risk at standard doses
→ Absolute risk (MHRA): ~14–20 extra per 1,000 with 5 years of combined HRT from ~50; validate before correcting
→ Sequential for <12m amenorrhoea; continuous for ≥12m
→ Always ask dyspareunia; vaginal oestrogen addresses GSM specifically
→ Start HRT immediately; every month without oestrogen = bone loss
→ NICE NG23: no mandatory stop at 5 years; decision based on symptoms + risk